CDK4 and acute myeloid leukemia: While PROTACs targeting only CDK6 degradation did not provide added benefit compared to the CDK4/CDK6 inhibitor palbociclib, PROTAC-mediated GSPT1 degradation yielded strong antiproliferative effects in both AML subtypes examined.